Corpus ID: 30217035

Rational Design of Combinations for the Treatment of Advanced Cancer

@article{Komiya2016RationalDO,
  title={Rational Design of Combinations for the Treatment of Advanced Cancer},
  author={T. Komiya},
  journal={Cancer clinical trials},
  year={2016},
  volume={1},
  pages={122}
}
  • T. Komiya
  • Published 2016
  • Medicine
  • Cancer clinical trials
  • Despite our enormous effort and progress in medicine, cancer remains a top health issue worldwide. According to recent statistics, more than eight million people annually succumb to the disease in the world [1]. It is clear that we must work much harder in order to eliminate this disease in the next several decades. We have a hope, however, that can encourage us to do so and move forward: cancer immunotherapy. Systemic immunotherapy for the treatment of cancer has been investigated for many… CONTINUE READING
    1 Citations

    Topics from this paper

    Types of Cancer and Surgery in Rats (Rattus norvegicus)
    • 1
    • PDF

    References

    SHOWING 1-10 OF 21 REFERENCES
    Role of IL-2 in cancer immunotherapy
    • 139
    Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    • 4,956
    • PDF
    Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    • 5,110
    • PDF
    Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    • 4,112
    • PDF
    Nivolumab in previously untreated melanoma without BRAF mutation.
    • 3,536
    • PDF
    Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    • G. Giaccone, R. Herbst, +15 authors D. Johnson
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 1,731
    • PDF
    PD-1 blockade in tumors with mismatch repair deficiency.
    • J. Uram, Hao Wang, +16 authors L. Diaz
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2015
    • 2,143
    • PDF
    Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    • R. Herbst, G. Giaccone, +14 authors D. Johnson
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 1,712
    • PDF